Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial

INTRODUCTION: In the randomized Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 10 trial, once-daily orally administered semaglutide—the first oral glucagon-like peptide 1 receptor agonist (GLP-1RA)—was similarly tolerated with comparable (at 7 mg) or better (at 14 mg) efficacy versus the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hitoshi, Hansen, Brian B., Langer, Jakob, Horio, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846658/
https://www.ncbi.nlm.nih.gov/pubmed/33460016
http://dx.doi.org/10.1007/s13300-020-00985-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846658/
https://www.ncbi.nlm.nih.gov/pubmed/33460016
http://dx.doi.org/10.1007/s13300-020-00985-w

Ejemplares similares